Robert L. Dell Angelo

Robert L. Dell Angelo

Retired Partner

Robert Dell Angelo retired from Munger, Tolles & Olson’s litigation department in December 2022.

Mr. Dell Angelo's practice included all major commercial litigation, with an emphasis on defending companies in securities matters and disputes over corporate control. In addition to guiding large companies through shareholder-initiated securities claims, Mr. Dell Angelo frequently handled significant matters for biotechnology companies, utilizing his background as a medical doctor.

Mr. Dell Angelo also led numerous corporate investigations, including inquiries regarding alleged misrepresentations by management.

Prior to law school, Mr. Dell Angelo obtained an M.D. from the College of Physicians and Surgeons, Columbia University’s medical school. He spent two years in post-graduate surgical training at St. Luke’s Roosevelt Hospital, a New York City trauma center, and received training in each of the surgical subspecialties. He is a diplomate of the National Board of Medical Examiners.

Experience

Key Representations

  • Intel Corporation and its directors in securities and derivative actions filed following the disclosure of alleged flaws in Intel chips; defendants obtained dismissals with prejudice in all cases.   
  • The Founders of Beats by Dre in a securities fraud action brought by Monster and Noel Lee following the sale of Beats by Dre to Apple; obtained summary judgment in favor of clients and an award for their legal fees.
  • Maker Studios in defending an action brought by Maker’s founder and former CEO who sought to regain control of Maker and prevent its sale to the Walt Disney Company; the case resolved following judgment in favor of Maker and with a motion for recovery of its legal fees pending.
  • Defense of numerous securities actions, including on behalf of The Coca-Cola Co., Northrop Grumman, 3M Company, 99 Cents Only Stores, Danaher, Playboy Enterprises, Merrill Lynch, and Avalanche Biotechnologies.
  • Numerous internal investigations for publicly traded corporations, including representation of the Audit Committee and other independent directors of Baxter International, Inc. in overseeing the company’s internal investigation, earnings restatement and self-reporting to the SEC after the discovery that employees were effecting intra-company transactions for the purpose of generating foreign currency gains.  
  • Rent-A-Center, Inc. in expedited trial in Delaware establishing its right to terminate a proposed merger, followed by a settlement enabling it to collect a termination fee of $92.5 million.
  • View Inc. in expedited proceedings in Delaware challenging its capital structure; the case resolved with a judgment confirming View’s capital structure, which cleared the way for a transformative investment by SoftBank.
  • A major pharmaceutical company in a dispute over milestone payments related to a treatment for relapsed multiple myeloma.